NASDAQ:SLS SELLAS Life Sciences Group Q2 2024 Earnings Report $1.92 0.00 (0.00%) Closing price 08/28/2025 04:00 PM EasternExtended Trading$1.94 +0.03 (+1.30%) As of 08:59 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast SELLAS Life Sciences Group EPS ResultsActual EPS-$0.13Consensus EPS -$0.16Beat/MissBeat by +$0.03One Year Ago EPSN/ASELLAS Life Sciences Group Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ASELLAS Life Sciences Group Announcement DetailsQuarterQ2 2024Date8/13/2024TimeAfter Market ClosesConference Call DateTuesday, August 13, 2024Conference Call Time7:00AM ETUpcoming EarningsSELLAS Life Sciences Group's Q3 2025 earnings is scheduled for Wednesday, November 12, 2025, with a conference call scheduled at 7:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) SELLAS Life Sciences Group Earnings HeadlinesSELLAS Life Sciences Group Target of Unusually High Options Trading (NASDAQ:SLS)August 20, 2025 | americanbankingnews.comSellas Life Sciences: SLS009's Phase 2 Sets Up A Promising 2026August 19, 2025 | seekingalpha.comHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvidia at $1.10 reveals AI’s Next Magnificent Seven… including one stock he says could become America’s next trillion-dollar giant.August 29 at 2:00 AM | The Oxford Club (Ad)Sellas Life Sciences Reports Q2 2025 Financial ResultsAugust 13, 2025 | msn.comSellas Life Sciences reports Q2 EPS (7c), consensus (8c)August 12, 2025 | msn.comSELLAS Life Sciences Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateAugust 12, 2025 | finance.yahoo.comSee More SELLAS Life Sciences Group Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like SELLAS Life Sciences Group? Sign up for Earnings360's daily newsletter to receive timely earnings updates on SELLAS Life Sciences Group and other key companies, straight to your email. Email Address About SELLAS Life Sciences GroupSELLAS Life Sciences Group (NASDAQ:SLS), a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.View SELLAS Life Sciences Group ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor After Earnings Miss, Walmart Is Still a Top Consumer Staples PlayRoyal Caribbean Earnings Beat Fuels Strong 2025 OutlookDLocal Stock Soars 43% After Earnings Beat and Raised GuidanceGreen Dot's 30% Rally: Turnaround Takes Off on Explosive EarningsElbit Systems Jumps on Record Earnings and a $1.6B ContractBrinker Serves Up Earnings Beat, Sidesteps Cost Pressures Upcoming Earnings Salesforce (9/3/2025)Broadcom (9/4/2025)Oracle (9/8/2025)Synopsys (9/9/2025)Adobe (9/11/2025)FedEx (9/18/2025)AutoZone (9/23/2025)Cintas (9/24/2025)Micron Technology (9/24/2025)Costco Wholesale (9/25/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access